Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about BioAdaptives, Inc.
BioAdaptives, Inc. News
BioAdaptives, Inc. Quantitative Score
About BioAdaptives, Inc.
BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.
BioAdaptives, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
BioAdaptives, Inc. Financials
Table Compare
Compare BDPT metrics with: | |||
|---|---|---|---|
Earnings & Growth | BDPT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BDPT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BDPT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BDPT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
BioAdaptives, Inc. Income
BioAdaptives, Inc. Balance Sheet
BioAdaptives, Inc. Cash Flow
BioAdaptives, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
BioAdaptives, Inc. Executives
| Name | Role |
|---|---|
| Mr. James E. Keener | Chief Executive Officer & Chairman |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. James E. Keener | Chief Executive Officer & Chairman | Male | 1971 | -- |
BioAdaptives, Inc. Insider Trades
| Date | 1 Jul |
| Name | FRISSORA MARK P |
| Role | Director |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 847 |
| Date | 1 Jun |
| Name | FRISSORA MARK P |
| Role | Director |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 713 |
| Date | 1 May |
| Name | FRISSORA MARK P |
| Role | Director |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 694 |
| Date | 15 Feb |
| Name | FRISSORA MARK P |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 455 |
| Date | 15 Mar |
| Name | FRISSORA MARK P |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 479 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 Jul | FRISSORA MARK P | Director | Acquired | J-Other | 847 |
| 1 Jun | FRISSORA MARK P | Director | Acquired | J-Other | 713 |
| 1 May | FRISSORA MARK P | Director | Acquired | J-Other | 694 |
| 15 Feb | FRISSORA MARK P | Director | Acquired | A-Award | 455 |
| 15 Mar | FRISSORA MARK P | Director | Acquired | A-Award | 479 |